ReviewInternational journal of molecular sciences2022
A Decade of CRISPR-Cas Gnome Editing in
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Transgenesis and targeted mutagenesis in the human-parasitic nematodeFrontiers in parasitology · 2026Review
- A single-copy knock-in system: one plasmid to target all chromosomes in C. elegans.G3 (Bethesda, Md.) · 2025Article
- Aberrant X chromosome dosage compensation causes hybrid male inviability inProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Transcription-coupled repair: tangled up in convoluted repair.The FEBS journal · 2025Review
- Nematode mind: exploring the role of the RNA interference pathway in learning, memory and beyond.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Synthetic guide sequence to generate CRISPR-Cas9 entry strains inmicroPublication biology · 2025Article
- A dominantmicroPublication biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
CRISPR-Cas allows us to introduce desired genome editing, including mutations, epitopes, and deletions, with unprecedented efficiency. The development of CRISPR-Cas has progressed to such an extent that it is now applicable in various fields, with the help of model organisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.